Serina Therapeutics, Inc.

SER

$2.56

-4.83%

N/A-$0.13

Healthcare

Biotechnology

AMEX

Active Trading

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, ...

Fundamental Analysis of SER

Key Strengths

Proprietary POZ platform technology with potential to improve drug delivery for CNS diseases

Pipeline addressing large markets: Parkinson's disease, pain, and epilepsy

Risk Factors

Clinical-stage company with no commercial products and no recurring revenue

High cash burn rate, requiring additional funding and causing dilution risk

Profitability

Net Margin0.00%

Operating Margin0.00%

Valuation

P/E Ratio-1.43x

Current Ratio6.65

Efficiency

ROE-222.42%

ROA-82.03%

Fundamental Analysis of SER

Serina Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurological disorders and pain using its proprietary POZ platform. The company's lead candidate, SER 252, is a POZ conjugate for Parkinson's disease, with additional candidates in pain and epilepsy. The POZ platform aims to improve drug half-life and delivery efficiency, offering potential competitive advantages in CNS drug development. Financially, Serina is in a pre-revenue stage, with minimal sales and substantial R&D and administrative expenses. The company has a market cap of approximately $42 million and trades at $2.82 per share. Key financial metrics show negative margins across the board (net margin -163.6%, operating margin -188%), negative returns on equity and assets (-402% and -77.9% respectively), and a high price-to-sales ratio of 325, reflecting investor expectations for future growth. The company has a current ratio of 4.18 and a cash ratio of 3.87, indicating strong liquidity in the short term, but negative operating cash flow and free cash flow raise concerns about its cash runway. The company's reliance on external financing and the dilutive nature of future capital raises are significant risks. Additionally, clinical development is subject to regulatory and trial success uncertainties. The stock's beta is very low (0.029), suggesting low volatility, but its high enterprise value-to-sales and poor profitability metrics indicate that valuation is based on speculative potential rather than current financial performance. Analyst sentiment is cautious due to lack of revenue and high burn rate. The company has a small number of employees (16) and limited resources, which may impede its ability to advance multiple candidates. Long-term potential depends on successful clinical trials and eventual commercialization. The medium-term outlook hinges on upcoming data readouts and funding. Short-term prospects are muted given operational losses and no clear revenue catalyst. Overall, the fundamental analysis suggests a 'hold' rating, suitable for investors with high risk tolerance and speculative interest in biotech.

Key Strengths of SER

Proprietary POZ platform technology with potential to improve drug delivery for CNS diseases
Pipeline addressing large markets: Parkinson's disease, pain, and epilepsy
Strong liquidity position with current ratio above 4, providing near-term cash runway
Low beta suggests less market volatility, offering stability in a speculative sector
Experienced management team and established research partnerships
Positive early clinical data for lead candidate SER 252
Scalable platform potential for multiple drug conjugates and RNA vaccines

Risk Factors of SER

Clinical-stage company with no commercial products and no recurring revenue
High cash burn rate, requiring additional funding and causing dilution risk
Clinical trials may fail to show efficacy or safety, leading to write-downs
Regulatory hurdles in drug approval process
Small company with limited resources and manpower
Patent and intellectual property protection uncertainties
Competitive landscape with larger players in CNS therapeutics
Dependence on successful integration of POZ platform with candidates

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$40.34M

-1.4x

P/E Ratio

0.0x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin0.00%

Net Profit Margin0.00%

Debt/Equity Ratio0.17

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of SER

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of SER

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of SER

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	6.653	—	—	Flat
Quick Ratio	—	6.653	—	—	Flat
Debt / Equity	—	0.171	—	—	Flat

Valuation of SER

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-0.88x	—	—	Flat
P/B	—	1.70x	—	—	Flat

Supply Chain of SER

RELATIONS

Upstream

Enable Injections, Inc.Contract Development & Manufacturing Organizations (CDMOs) — API & Drug ProductHudsonAlpha Institute for BiotechnologyMerck KGaA (Sigma-Aldrich)XETRA:MRKThe Scripps Research InstituteRaw Chemical & Monomer Suppliers

Downstream

Pfizer Inc.NYSE:PFEEnable Injections, Inc.Neuroscience Trials Australia (NTA)Parkinson's AustraliaAstraZeneca plcNASDAQ:AZN

Proxies

Neurocrine Biosciences, Inc.NASDAQ:NBIX Acorda Therapeutics, Inc.NASDAQ:ACOR Supernus Pharmaceuticals, Inc.NASDAQ:SUPN

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer